Hypothesis: A possible role for interferon in the treatment of idiopathic myelofibrosis

H. Hasselbalch*

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    It is proposed that interferon may be an active agent in the treatment of patients with idiopathic myelofibrosis. In this disorder the megakaryocyte cell lineage plays a major role in the deposition of bone marrow collagen by the release of growth promoting factors, including platelet-derived growth factor, which are mitogenic for fibroblast proliferation. Interferon reduces collagen deposition in the bone marrow by suppressing the activity of the proto-oncogene, which is involved in the production of growth factors from abnormal megakaryocytes and platelets. A direct myeloid cytoreductive effect of interferon upon the megakaryocyte proliferation contributes to reducing growth factor activity in the bone marrow. Finally, interferon induces monocytoid differentiation, thereby increasing bone marrow collagenase-activity. Thus, interferon has several actions, which in concert might reduce bone marrow collagen in myelofibrosis.

    Sider (fra-til)345-347
    Antal sider3
    TidsskriftMedical Hypotheses
    Udgave nummer4
    StatusUdgivet - dec. 1988


    Udforsk hvilke forskningsemner 'Hypothesis: A possible role for interferon in the treatment of idiopathic myelofibrosis' indeholder.